Interferon and ribavirin combination therapy: indications and schedules

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C virus (HCV) infection management has advanced significantly.
• Interferon (IFN) and ribavirin combination therapy offers improved treatment outcomes.
• Treatment decisions involve patient age, health, cirrhosis risk, and cure probability.

Purpose of the Study:

• To evaluate the efficacy of interferon and ribavirin combination therapy for chronic hepatitis C.
• To compare combination therapy outcomes with interferon monotherapy.
• To determine optimal treatment durations based on patient characteristics and viral factors.

Main Methods:

• Standard dose combination therapy: IFN-a (3x10^6 IU TIW) plus ribavirin (1000-1200 mg daily).
• Treatment durations varied: six months for favorable genotypes (2, 3), up to 48 weeks for unfavorable genotypes (1 with high viral load).
• Evaluated sustained biochemical and virological response rates.

Main Results:

• Combination therapy demonstrated 2-3 times higher sustained response rates compared to IFN alone.
• Six months of therapy is sufficient for genotypes 2 and 3.
• 48 weeks of therapy is recommended for genotype 1 with high viral load.
• Combination therapy is superior and better tolerated in patients with compensated cirrhosis.

Conclusions:

• Interferon and ribavirin combination therapy is the standard of care for naive and relapsed hepatitis C patients.
• Treatment duration should be individualized based on viral genotype and baseline viral load.
• Future research should focus on optimized dosing and novel IFN formulations for further improvement.